Cargando…

Developing Therapies for Peanut Allergy

Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Bublin, Merima, Breiteneder, Heimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548240/
https://www.ncbi.nlm.nih.gov/pubmed/25531161
http://dx.doi.org/10.1159/000369340
_version_ 1783255805991059456
author Bublin, Merima
Breiteneder, Heimo
author_facet Bublin, Merima
Breiteneder, Heimo
author_sort Bublin, Merima
collection PubMed
description Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not feasible due to the high risk of severe systemic side effects. The allergen-specific approaches under preclinical and clinical investigation comprise subcutaneous, oral, sublingual and epicutaneous immunotherapy with whole-peanut extracts as well as applications of hypoallergenic peanut allergens or T cell epitope peptides. Allergen-nonspecific approaches include monoclonal anti-IgE antibodies, TCM herbal formulations and Toll-like receptor 9-based immunotherapy. The potential of genetically engineered plants with reduced allergen levels is being explored as well as the beneficial influence of lactic acid bacteria and soybean isoflavones on peanut allergen-induced symptoms. Although the underlying mechanisms still need to be elucidated, several of these strategies hold great promise. It can be estimated that individual strategies or a combination thereof will result in a successful immunotherapy regime for peanut-allergic individuals within the next decade.
format Online
Article
Text
id pubmed-5548240
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-55482402017-08-08 Developing Therapies for Peanut Allergy Bublin, Merima Breiteneder, Heimo Int Arch Allergy Immunol Article Peanut allergy is an IgE-mediated, persisting immune disorder that is of major concern worldwide. Currently, no routine immunotherapy is available to treat this often severe and sometimes fatal food allergy. Traditional subcutaneous allergen immunotherapy with crude peanut extracts has proven not feasible due to the high risk of severe systemic side effects. The allergen-specific approaches under preclinical and clinical investigation comprise subcutaneous, oral, sublingual and epicutaneous immunotherapy with whole-peanut extracts as well as applications of hypoallergenic peanut allergens or T cell epitope peptides. Allergen-nonspecific approaches include monoclonal anti-IgE antibodies, TCM herbal formulations and Toll-like receptor 9-based immunotherapy. The potential of genetically engineered plants with reduced allergen levels is being explored as well as the beneficial influence of lactic acid bacteria and soybean isoflavones on peanut allergen-induced symptoms. Although the underlying mechanisms still need to be elucidated, several of these strategies hold great promise. It can be estimated that individual strategies or a combination thereof will result in a successful immunotherapy regime for peanut-allergic individuals within the next decade. 2014-12-20 2014 /pmc/articles/PMC5548240/ /pubmed/25531161 http://dx.doi.org/10.1159/000369340 Text en http://creativecommons.org/licenses/by/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Bublin, Merima
Breiteneder, Heimo
Developing Therapies for Peanut Allergy
title Developing Therapies for Peanut Allergy
title_full Developing Therapies for Peanut Allergy
title_fullStr Developing Therapies for Peanut Allergy
title_full_unstemmed Developing Therapies for Peanut Allergy
title_short Developing Therapies for Peanut Allergy
title_sort developing therapies for peanut allergy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548240/
https://www.ncbi.nlm.nih.gov/pubmed/25531161
http://dx.doi.org/10.1159/000369340
work_keys_str_mv AT bublinmerima developingtherapiesforpeanutallergy
AT breitenederheimo developingtherapiesforpeanutallergy